Clovis Oncology News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.02.19	Clovis Oncology Announces 2018 Operating Results (Businesswire)
22.02.19	Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference (Businesswire)
12.02.19	Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26 (Businesswire)
24.01.19	Clovis Oncology Announces European Commission Authorization of Rubraca®? (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer (Businesswire)
07.01.19	Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018 (Businesswire)
02.01.19	Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference (Businesswire)
14.12.18	CHMP gibt positive Stellungnahme für die neue Indikation der Rubraca®-Tabletten von Clovis Oncology ? (Rucaparib) als Erhaltungstherapie für Frauen mit rückläufigem Eierstockkrebs ab (Businesswire)
04.12.18	Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca® (Businesswire)
20.11.18	Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035 (Businesswire)
07.11.18	Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference (Businesswire)
01.11.18	FDA Approves 3rd Humira Biosimilar, CLVS Tanks On Q3 Results, CRY On Watch (RTTNews)
30.10.18	Clovis Oncology Announces Third Quarter 2018 Operating Results (Businesswire)
23.10.18	ADAP Down 46% This Month, CLVS Abuzz, ADRO Awaits Data In Nov. (RTTNews)
16.10.18	Clovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30 (Businesswire)
11.10.18	Clovis Oncology Appoints Two New Directors to its Board (Businesswire)
03.10.18	Clovis Oncology to Highlight Results from Rubraca® (rucaparib) TRITON Prostate Program at ESMO 2018 Congress (Businesswire)
02.10.18	Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC) (Businesswire)
19.09.18	Clovis Oncology, Executives Charged With Misleading Investors About Cancer Drug (RTTNews)
06.09.18	Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference (Businesswire)
08.08.18	Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial (Businesswire)
01.08.18	Clovis Oncology Announces Second Quarter 2018 Operating Results (Businesswire)
18.07.18	Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1 (Businesswire)
06.07.18	BIIB One Step Closer, MBVX To Be Delisted, RGLS In The Red On Pink Slip Woes (RTTNews)
05.07.18	Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca®? (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer (Businesswire)
11.06.18	Clovis Oncology to Present at the Goldman Sachs 39th Annual Global Healthcare Conference 2018 (Businesswire)
04.06.18	Clovis Oncology Submits Application to EMA to Expand Use of Rubraca®? (rucaparib) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer (Businesswire)
30.05.18	AKER Withdraws 510(K), TTOO Turns Head, CPRX, LOXO To Face FDA In Nov. (RTTNews)
16.05.18	Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting (Businesswire)
09.05.18	Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018 (Businesswire)
08.05.18	Clovis Oncology Announces First Quarter 2018 Operating Results (Businesswire)
24.04.18	Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8 (Businesswire)
17.04.18	Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock (Businesswire)
16.04.18	Clovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Businesswire)
06.04.18	Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer (Businesswire)
01.04.18	An Ear To The Pharma: 5 Stocks To Watch This Week (RTTNews)
28.03.18	Biotech Stocks Facing FDA Decision In April (RTTNews)
26.03.18	CHMP Says Yes To CLVS, No To PTLA, NVCN Put On Notice, OGEN To Report Data In Q2 (RTTNews)
23.03.18	Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe (Businesswire)
23.03.18	CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets (Businesswire)
08.03.18	Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035 (Businesswire)
07.03.18	Clovis Oncology to Present at the Barclays Global Healthcare Conference (Businesswire)
22.02.18	ACIP Backs HEPLISAV-B, GMED Hits New High, GWPH's Focal Seizures Trial Fails (RTTNews)
12.02.18	Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26 (Businesswire)
04.01.18	Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference (Businesswire)
19.12.17	Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018 (Businesswire)
06.12.17	NVO Gets FDA Nod, GALT Down But Not Out, BIOC Gets A Boost, CUR Excited (RTTNews)
05.12.17	Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application (Businesswire)
09.11.17	Clovis Oncology to Present at the Stifel 2017 Healthcare Conference (Businesswire)
01.11.17	Clovis Oncology Announces Third Quarter 2017 Operating Results (Businesswire)
10.10.17	CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	29.71	2.10 %	K V
Holcim	92.22	1.47 %	K V
Sika	230.00	1.28 %	K V
Kuehne+Nagel Int	204.40	1.19 %	K V
Swisscom	514.50	1.08 %	K V
Novartis	98.19	-0.40 %	K V
Roche Hldg G	288.60	-0.93 %	K V
CieFinRichemont	175.95	-0.98 %	K V
Sonova Hldg	305.70	-1.07 %	K V
Givaudan	3’875.00	-1.07 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Clovis Oncology Inc.

Aktien Top/Flop

Meistgelesene Nachrichten